CDMO MabPlex expands cGMP manufacturing facilities in China

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Roland Magnusson)
(Image: iStock/Roland Magnusson)

Related tags Manufacturing

MabPlex International is expanding its biomanufacturing facilities in China to meet biologic demand for “the foreseeable future.”

According to the company, the current 275,000 square-foot facility will be running at full capacity soon, after being converted to ADC manufacturing and development space.

The new 428,000 square-foot facility is expected to be completed by August of 2017 and will be used for mAb and other biologic manufacturing.

The facility will feature six 2,000L bioreactor suites or six independent manufacturing lines (6x25L, 6x200L, 6x500L and 12x2,000L single use bioreactors).

It will also include six purification suites, a 37,000 square-foot cGMP warehouse, and fill finish lines with capabilities up to 10,000 vials/hr. for mAb and 12,000 vials/hr. for ADC.

Utility and HVAC validation is expected to be finished by December 2017 and the fill/finish facility will be validated by March of 2018.

Qibin Liang, President of MabPlex said that the expansion will help the company meet its customers’ biologics needs for “the foreseeable future​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more